MX2023013538A - Metodos para tratar la depresion y la ansiedad. - Google Patents

Metodos para tratar la depresion y la ansiedad.

Info

Publication number
MX2023013538A
MX2023013538A MX2023013538A MX2023013538A MX2023013538A MX 2023013538 A MX2023013538 A MX 2023013538A MX 2023013538 A MX2023013538 A MX 2023013538A MX 2023013538 A MX2023013538 A MX 2023013538A MX 2023013538 A MX2023013538 A MX 2023013538A
Authority
MX
Mexico
Prior art keywords
anxiety
rho kinase
methods
patients
inhibitors
Prior art date
Application number
MX2023013538A
Other languages
English (en)
Inventor
Sven Jacobson
Thomas Macallister
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of MX2023013538A publication Critical patent/MX2023013538A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al tratamiento de pacientes con depresión y/o ansiedad con dosis altas de inhibidores de la quinasa rho. La dosis máxima de un inhibidor de la quinasa rho, basado en clorhidrato de fasudilo como agente ejemplar, es superior a 70 mg por día basado en una formulación de liberación inmediata. La dosis comparable con otros inhibidores se selecciona basándose en equivalentes molares y/o afinidades de unión a la quinasa rho. Los pacientes tratables tienen uno o más trastornos depresivos y/o uno o más trastornos de ansiedad.
MX2023013538A 2021-05-19 2022-05-16 Metodos para tratar la depresion y la ansiedad. MX2023013538A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163190523P 2021-05-19 2021-05-19
PCT/US2022/029419 WO2022245719A1 (en) 2021-05-19 2022-05-16 Methods of treating depression and anxiety

Publications (1)

Publication Number Publication Date
MX2023013538A true MX2023013538A (es) 2023-11-27

Family

ID=84140968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013538A MX2023013538A (es) 2021-05-19 2022-05-16 Metodos para tratar la depresion y la ansiedad.

Country Status (3)

Country Link
CA (1) CA3217563A1 (es)
MX (1) MX2023013538A (es)
WO (1) WO2022245719A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023097151A1 (en) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
CN115998736B (zh) * 2023-03-28 2023-06-23 中国人民解放军军事科学院军事医学研究院 Y-27632在特异性抑制幻觉作用中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE551059T1 (de) * 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
EP3828172A1 (en) * 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US20210386755A1 (en) * 2018-10-15 2021-12-16 National University Corporation Tokai National Higher Education And Research System Antipsychotic and use thereof

Also Published As

Publication number Publication date
WO2022245719A1 (en) 2022-11-24
CA3217563A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
MX2023013538A (es) Metodos para tratar la depresion y la ansiedad.
MX2023013536A (es) Metodos para tratar la depresion y la ansiedad.
CR20230310A (es) Inhibidores de prmt5
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2021008342A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
MX2007015863A (es) Inhibidores de esfingosina cinasa.
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
CR20220236A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
MX2020010322A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021014175A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
BRPI0509653A (pt) inibidores cinesina mitótica
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
WO2021232067A8 (en) Stat3 inhibition for treatment and prevention of human coronavirus infection
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
CL2022000214A1 (es) Inhibidores de enzimas
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.